On August 3, 2022 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, reported that management plans to participate in three upcoming investor conferences (Press release, Allogene, AUG 3, 2022, View Source [SID1234617358]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

42nd Annual Canaccord Genuity Growth Conference
Thursday, August 11, 2022
Noon PT/3:00PM ET

H.C. Wainwright 24th Annual Global Investment Conference
Monday, September 12, 2022
Presentation time to be posted to www.allogene.com

Baird 2022 Global Healthcare Conference
Tuesday, September 13, 2022
12:45PM PT/3:45PM ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.